139 related articles for article (PubMed ID: 38330767)
21. [Molecular-integrated risk profile: An opportunity for therapeutic de-escalation in intermediate and high-intermediate risk endometrial cancer].
Espenel S; Pointreau Y; Genestie C; Durdux C; Haie-Meder C; Chargari C
Cancer Radiother; 2022 Oct; 26(6-7):931-937. PubMed ID: 36031498
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
23. TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
Similä-Maarala J; Soovares P; Pasanen A; Ahvenainen T; Vahteristo P; Bützow R; Lassus H
Gynecol Oncol; 2022 Jun; 165(3):577-584. PubMed ID: 35370008
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy.
Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J
Pathol Res Pract; 2022 Aug; 236():153990. PubMed ID: 35749914
[TBL] [Abstract][Full Text] [Related]
25. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.
Chung YS; Woo HY; Lee JY; Park E; Nam EJ; Kim S; Kim SW; Kim YT
Am J Obstet Gynecol; 2021 Apr; 224(4):370.e1-370.e13. PubMed ID: 33039397
[TBL] [Abstract][Full Text] [Related]
26. Characteristics and outcomes of surgically staged multiple classifier endometrial cancer.
Bogani G; Betella I; Multinu F; Casarin J; GhezzI F; Sorbi F; VizziellI G; Petrillo M; Cianci S; Berretta R; PaolinI B; FanfanI F; De Vitis L; Scambia G; Mariani A; Colombo N; Raspagliesi F
Eur J Surg Oncol; 2024 Jan; 50(1):107269. PubMed ID: 37984242
[TBL] [Abstract][Full Text] [Related]
27. Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma.
Ravaggi A; Capoferri D; Ardighieri L; Ghini I; Ferrari F; Romani C; Bugatti M; Zanotti L; Vrede S; Tognon G; Pijnenborg JMA; Sartori E; Calza S; Bignotti E; Odicino F
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358847
[TBL] [Abstract][Full Text] [Related]
28. Analysis of patients with endometrial carcinoma using the ProMise classifier: a pilot study from India.
Dahiya A; Rajadurai A; Daniel S; Sebastian A; Thomas DS; Thomas V; George R; Ram TS; Sathyamurthy A; Rebekah G; Peedicayil A; Pai R; Thomas A
Arch Gynecol Obstet; 2024 Apr; 309(4):1499-1508. PubMed ID: 37707553
[TBL] [Abstract][Full Text] [Related]
29. Impact of the new molecular classification of endometrial cancer: A French cohort study.
Benichou J; Schwall C; Sastre-Garau X; Méreaux J; Miailhe G; Bendifallah S; Haddad B; Touboul C; Mitri-Frangieh R; Dabi Y
Gynecol Oncol; 2022 Sep; 166(3):515-521. PubMed ID: 35843738
[TBL] [Abstract][Full Text] [Related]
30. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women.
He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T
Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323
[TBL] [Abstract][Full Text] [Related]
31. The prognosis of endometrial cancers stratified with conventional risk factors and modified molecular classification.
Yamazaki H; Asano H; Hatanaka KC; Matsuoka R; Konno Y; Matsuno Y; Hatanaka Y; Watari H
Cancer Sci; 2022 Sep; 113(9):3134-3147. PubMed ID: 35707843
[TBL] [Abstract][Full Text] [Related]
32. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.
Kommoss FK; Karnezis AN; Kommoss F; Talhouk A; Taran FA; Staebler A; Gilks CB; Huntsman DG; Krämer B; Brucker SY; McAlpine JN; Kommoss S
Br J Cancer; 2018 Aug; 119(4):480-486. PubMed ID: 30050154
[TBL] [Abstract][Full Text] [Related]
33. Molecular testing of endometrial carcinoma in real-world clinical practice.
Bednaříková M; Hausnerová J; Minář L; Taslerová R; Vinklerová P; Ehrlichová L; Trizuljak J; Blaháková I; Princ D; Matulová K; Ovesná P; Slabý O; Weinberger V
Klin Onkol; 2023; 36(3):215-223. PubMed ID: 37353351
[TBL] [Abstract][Full Text] [Related]
34. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
Arciuolo D; Travaglino A; Raffone A; Raimondo D; Santoro A; Russo D; Varricchio S; Casadio P; Inzani F; Seracchioli R; Mollo A; Mascolo M; Zannoni GF
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232987
[TBL] [Abstract][Full Text] [Related]
35. Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population.
Kang N; Zhang X; Wang Z; Dai Y; Lu S; Su W; Gai F; Zhu C; Shen D; Wang J
Pathol Res Pract; 2024 Feb; 254():155152. PubMed ID: 38277742
[TBL] [Abstract][Full Text] [Related]
36. Molecular-based classification of endometrial carcinoma in Northern Thailand: impact on prognosis and potential for implementation in resource-limited settings.
Dankai W; Pongsuvareeyakul T; Phinyo P; Tejamai C; Teerapakpinyo C; Cheewakriangkrai C; Lekawanvijit S; Siriaunkgul S; Khunamornpong S
BMC Womens Health; 2023 Nov; 23(1):605. PubMed ID: 37964201
[TBL] [Abstract][Full Text] [Related]
37. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma.
Krämer P; Talhouk A; Brett MA; Chiu DS; Cairns ES; Scheunhage DA; Hammond RFL; Farnell D; Nazeran TM; Grube M; Xia Z; Senz J; Leung S; Feil L; Pasternak J; Dixon K; Hartkopf A; Krämer B; Brucker S; Heitz F; du Bois A; Harter P; Kommoss FKF; Sinn HP; Heublein S; Kommoss F; Vollert HW; Manchanda R; de Kroon CD; Nijman HW; de Bruyn M; Thompson EF; Bashashati A; McAlpine JN; Singh N; Tinker AV; Staebler A; Bosse T; Kommoss S; Köbel M; Anglesio MS
Clin Cancer Res; 2020 Oct; 26(20):5400-5410. PubMed ID: 32737030
[TBL] [Abstract][Full Text] [Related]
38. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
Horeweg N; Nout RA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Haverkort MAD; Mens JWM; Slot A; Wortman BG; de Boer SM; Stelloo E; Verhoeven-Adema KW; Putter H; Smit VTHBM; Bosse T; Creutzberg CL;
J Clin Oncol; 2023 Sep; 41(27):4369-4380. PubMed ID: 37487144
[TBL] [Abstract][Full Text] [Related]
39. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
[TBL] [Abstract][Full Text] [Related]
40. Enhanced Risk Stratification in Early-Stage Endometrial Cancer: Integrating
Joe S; Lee M; Kang J; Kim J; Hong SH; Lee SJ; Lee KH; Lee A
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
